[15], [19] Given the limitations in current quantitative dystrophin assays and CK, a validated biomarker for monitoring of drug activity in DMD is needed to facilitate drug development in this disease. Ultimately, clinically meaningful outcome measures such as the 6-minute walk test are required to evaluate therapeutic benefit in DMD [20], [21]. Here, DMD is linked to Duchenne muscular dystrophy.